A randomized trial of minoxidil in chemotherapy-induced alopecia

Madeleine Duvic; Noreen A. Lemak; Vicente Valero; Sharon R. Hymes; Kathryn L. Farmer; Gabriel N. Hortobagyi; Ronald J. Trancik; Bruce A. Bandstra; Linda D. Compton

doi:10.1016/S0190-9622(96)90500-9

A randomized trial of minoxidil in chemotherapy-induced alopecia

Madeleine Duvic, Noreen A. Lemak, Vicente Valero, Sharon R. Hymes, Kathryn L. Farmer, Gabriel N. Hortobagyi, Ronald J. Trancik, Bruce A. Bandstra, Linda D. Compton

Research output: Contribution to journal › Article › peer-review

121 Scopus citations

Abstract

Background: Hair loss is a side effect of many chemotherapeutic agents, and patients have even refused possibly palliative or lifesaving drugs because they could not accept temporary or prolonged baldness. Topical minoxidil has been shown to be effective for androgenetic alopecia and alopecia areata. Objective: Our purpose was to investigate the value and safety of minoxidil in chemotherapy-induced hair loss. Methods: Twenty-two women who were facing adjuvant chemotherapy after breast surgery were registered in a protocol that used a 2% minoxidil topical solution or a placebo in a randomized double-blind trial. Results: There was a statistically significant difference (favoring minoxidil) in the interval from maximal hair loss to first regrowth. Thus the period of baldness was shortened (mean, 50.2 days) in the minoxidil group. Conclusion: Minoxidil decreased the duration of alopecia caused by chemotherapy. There were no significant side effects.

Original language	English (US)
Pages (from-to)	74-78
Number of pages	5
Journal	Journal of the American Academy of Dermatology
Volume	35
Issue number	1
DOIs	https://doi.org/10.1016/S0190-9622(96)90500-9
State	Published - Jul 1996

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/S0190-9622(96)90500-9

Cite this

@article{22f80eca5e2e4545b67710a97568cc65,

title = "A randomized trial of minoxidil in chemotherapy-induced alopecia",

abstract = "Background: Hair loss is a side effect of many chemotherapeutic agents, and patients have even refused possibly palliative or lifesaving drugs because they could not accept temporary or prolonged baldness. Topical minoxidil has been shown to be effective for androgenetic alopecia and alopecia areata. Objective: Our purpose was to investigate the value and safety of minoxidil in chemotherapy-induced hair loss. Methods: Twenty-two women who were facing adjuvant chemotherapy after breast surgery were registered in a protocol that used a 2% minoxidil topical solution or a placebo in a randomized double-blind trial. Results: There was a statistically significant difference (favoring minoxidil) in the interval from maximal hair loss to first regrowth. Thus the period of baldness was shortened (mean, 50.2 days) in the minoxidil group. Conclusion: Minoxidil decreased the duration of alopecia caused by chemotherapy. There were no significant side effects.",

author = "Madeleine Duvic and Lemak, {Noreen A.} and Vicente Valero and Hymes, {Sharon R.} and Farmer, {Kathryn L.} and Hortobagyi, {Gabriel N.} and Trancik, {Ronald J.} and Bandstra, {Bruce A.} and Compton, {Linda D.}",

note = "Funding Information: From the Division of Medicine, Departments of Medical Specialtiesa and Breast and Gynecologic Medical Onco1ogy,bT he University of Texas, M. D. Anderson Cancer Center, Houston, and The Upjohn Company, Kalamazoo. c Supported by a grant from The Upjohn Company. R. J. T. and L. D. C. are employed by Upjohn; B. A. B. is a contract worker employed by another company. Reprint requests: Madeleine Duvic, MD, Section of Dermatology, M. D. Anderson Cancer Center, Box 47, 1515 Holcombe Blvd., Houston, TX 77030. Copyright {\textcopyright} 1996 by the American Academy of Dermatology, Inc. 0190-9622/96 $5.00 + 0 1611/70262",

year = "1996",

month = jul,

doi = "10.1016/S0190-9622(96)90500-9",

language = "English (US)",

volume = "35",

pages = "74--78",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "1",

}

TY - JOUR

T1 - A randomized trial of minoxidil in chemotherapy-induced alopecia

AU - Duvic, Madeleine

AU - Lemak, Noreen A.

AU - Valero, Vicente

AU - Hymes, Sharon R.

AU - Farmer, Kathryn L.

AU - Hortobagyi, Gabriel N.

AU - Trancik, Ronald J.

AU - Bandstra, Bruce A.

AU - Compton, Linda D.

N1 - Funding Information: From the Division of Medicine, Departments of Medical Specialtiesa and Breast and Gynecologic Medical Onco1ogy,bT he University of Texas, M. D. Anderson Cancer Center, Houston, and The Upjohn Company, Kalamazoo. c Supported by a grant from The Upjohn Company. R. J. T. and L. D. C. are employed by Upjohn; B. A. B. is a contract worker employed by another company. Reprint requests: Madeleine Duvic, MD, Section of Dermatology, M. D. Anderson Cancer Center, Box 47, 1515 Holcombe Blvd., Houston, TX 77030. Copyright © 1996 by the American Academy of Dermatology, Inc. 0190-9622/96 $5.00 + 0 1611/70262

PY - 1996/7

Y1 - 1996/7

N2 - Background: Hair loss is a side effect of many chemotherapeutic agents, and patients have even refused possibly palliative or lifesaving drugs because they could not accept temporary or prolonged baldness. Topical minoxidil has been shown to be effective for androgenetic alopecia and alopecia areata. Objective: Our purpose was to investigate the value and safety of minoxidil in chemotherapy-induced hair loss. Methods: Twenty-two women who were facing adjuvant chemotherapy after breast surgery were registered in a protocol that used a 2% minoxidil topical solution or a placebo in a randomized double-blind trial. Results: There was a statistically significant difference (favoring minoxidil) in the interval from maximal hair loss to first regrowth. Thus the period of baldness was shortened (mean, 50.2 days) in the minoxidil group. Conclusion: Minoxidil decreased the duration of alopecia caused by chemotherapy. There were no significant side effects.

AB - Background: Hair loss is a side effect of many chemotherapeutic agents, and patients have even refused possibly palliative or lifesaving drugs because they could not accept temporary or prolonged baldness. Topical minoxidil has been shown to be effective for androgenetic alopecia and alopecia areata. Objective: Our purpose was to investigate the value and safety of minoxidil in chemotherapy-induced hair loss. Methods: Twenty-two women who were facing adjuvant chemotherapy after breast surgery were registered in a protocol that used a 2% minoxidil topical solution or a placebo in a randomized double-blind trial. Results: There was a statistically significant difference (favoring minoxidil) in the interval from maximal hair loss to first regrowth. Thus the period of baldness was shortened (mean, 50.2 days) in the minoxidil group. Conclusion: Minoxidil decreased the duration of alopecia caused by chemotherapy. There were no significant side effects.

UR - http://www.scopus.com/inward/record.url?scp=0029959347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029959347&partnerID=8YFLogxK

U2 - 10.1016/S0190-9622(96)90500-9

DO - 10.1016/S0190-9622(96)90500-9

M3 - Article

C2 - 8682968

AN - SCOPUS:0029959347

SN - 0190-9622

VL - 35

SP - 74

EP - 78

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 1

ER -

A randomized trial of minoxidil in chemotherapy-induced alopecia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this